ArticleAmerican journal of translational research2026
Psoralen regulates bone degenerative diseases by inhibiting APP phosphorylation to regulate MAPK and STAT3 signaling.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPsoralen can modulate bone metabolism pathways. This study investigated its effects on bone degenerative diseases, amyloid precursor protein (APP) phosphorylation, and the related pathways.
methodsThe Aβ40/Aβ42 levels in mouse serum were analyzed through enzyme-linked immunosorbent assay (ELISA) across ages. mRNA levels of APP, APH-1α, PEN-2, and RAGE were determined through polymerase chain reaction (PCR). Thereafter, three degenerative models, including knee osteoarthritis, osteoporosis, and intervertebral disc degeneration, were established. Mice with APP knockout were generated, and the pathology was evaluated at weeks 4-20 through safranin O staining, osteoclast counting (immunohistochemistry, IHC), and hematoxylin and eosin (H&E) staining. Subsequently, TNF-α and HA contents were examined by ELISA, and Col2 expression and apoptosis were also analyzed. Furthermore, the anti-osteoporotic mechanisms of psoralen were explored at the cellular and animal levels.
resultsAs the mice aged, the expression of p-APP increased significantly, while that of proteins involved in the pathway decreased markedly. By constructing an APP knockout mouse model, it was found that after APP knockout, the mice developed bone degenerative lesions, which intensified with age. Intervention with psoralen was effective for ameliorating the pathologic condition of bone degenerative lesions in mice, and inhibiting the progression of bone tissue pathology. Notably, this effect exhibited a dose-dependent trend. Besides, intervention with psoralen in osteoblasts promoted osteoblast proliferation and regulated the phosphorylation of MAPK, AKT, and STAT3. For osteoblasts treated with pathway inhibitors and psoralen, psoralen exerted its effects through the MAPK, AKT, and STAT3 signaling pathways.
conclusionThe phosphorylation of APP promotes the occurrence and progression of bone degenerative diseases. Psoralen regulates bone degenerative diseases by inhibiting APP phosphorylation, and regulating the MAPK and STAT3 signaling pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.